For the quarter ending 2025-09-30, CGEM had $30,515K increase in cash & cash equivalents over the period. -$36,915K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -50,610 | -118,556 |
| Equity-based compensation expense | 9,467 | 19,261 |
| Accretion on marketable securities | -1,358 | -4,017 |
| Depreciation and amortization | 79 | 153 |
| Prepaid expenses and other assets | -798 | -5,259 |
| Accounts payable | -739 | 779 |
| Accrued expenses and other liabilities | 5,486 | -3,643 |
| Net cash used in operating activities | -36,877 | -100,764 |
| Maturities of marketable securities | 80,000 | 294,572 |
| Purchase of marketable securities | 12,570 | 204,366 |
| Purchases of property and equipment | 38 | - |
| Net cash provided by (used in) investing activities | 67,392 | 90,206 |
| Issuance of common stock under equity-based compensation plans | 0 | 373 |
| Issuance of common stock and pre-funded warrants, net of issuance costs | 0 | 0 |
| Acquisition of noncontrolling interests | 0 | 0 |
| Net cash provided by financing activities | 0 | 373 |
| Net increase in cash and cash equivalents | 30,515 | -10,185 |
| Cash and cash equivalents at beginning of period | 83,005 | - |
| Cash and cash equivalents at end of period | 103,335 | - |
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)